Dimensional Fund Advisors LP lessened its position in shares of Cardlytics, Inc. (NASDAQ:CDLX - Free Report) by 21.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 498,120 shares of the company's stock after selling 139,907 shares during the period. Dimensional Fund Advisors LP owned 0.98% of Cardlytics worth $1,848,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Tallon Kerry Patrick acquired a new stake in Cardlytics during the 4th quarter worth about $37,000. Virtu Financial LLC acquired a new stake in Cardlytics during the fourth quarter worth approximately $62,000. Intech Investment Management LLC increased its holdings in Cardlytics by 31.3% in the fourth quarter. Intech Investment Management LLC now owns 19,310 shares of the company's stock worth $72,000 after purchasing an additional 4,607 shares in the last quarter. SG Americas Securities LLC increased its holdings in Cardlytics by 38.2% in the fourth quarter. SG Americas Securities LLC now owns 19,490 shares of the company's stock worth $72,000 after purchasing an additional 5,392 shares in the last quarter. Finally, Global Retirement Partners LLC lifted its stake in Cardlytics by 54.7% in the fourth quarter. Global Retirement Partners LLC now owns 19,800 shares of the company's stock valued at $73,000 after buying an additional 7,000 shares during the period. Institutional investors and hedge funds own 68.10% of the company's stock.
Cardlytics Trading Down 1.9%
NASDAQ:CDLX opened at $2.06 on Thursday. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. Cardlytics, Inc. has a one year low of $1.22 and a one year high of $9.85. The company has a market cap of $108.15 million, a PE ratio of -0.34 and a beta of 1.30. The firm has a 50-day moving average of $1.80 and a 200-day moving average of $2.94.
Insiders Place Their Bets
In other Cardlytics news, CEO Amit Gupta sold 46,857 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $159,313.80. Following the transaction, the chief executive officer now directly owns 418,637 shares in the company, valued at approximately $1,423,365.80. This trade represents a 10.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alexis Desieno sold 24,778 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $84,245.20. Following the completion of the sale, the chief financial officer now owns 140,948 shares of the company's stock, valued at approximately $479,223.20. The trade was a 14.95% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,938 shares of company stock valued at $244,017. Corporate insiders own 4.40% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently commented on CDLX shares. Evercore ISI reduced their price objective on shares of Cardlytics from $4.00 to $3.00 and set an "in-line" rating for the company in a research report on Thursday, March 13th. Needham & Company LLC restated a "hold" rating on shares of Cardlytics in a report on Thursday, March 13th. Finally, Lake Street Capital decreased their price target on shares of Cardlytics from $3.00 to $2.50 and set a "hold" rating for the company in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $5.20.
View Our Latest Research Report on CDLX
Cardlytics Profile
(
Free Report)
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardlytics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.
While Cardlytics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
